$1.51
1.34% day before yesterday
Nasdaq, Dec 27, 10:15 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Stock price

$1.51
-1.12 42.59% 1M
-6.08 80.10% 6M
-12.41 89.15% YTD
-10.89 87.82% 1Y
-1,078.46 99.86% 3Y
-36,521.38 100.00% 5Y
-1,069,867.29 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.02 1.34%
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Key metrics

Market capitalization $4.54m
Enterprise Value $4.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 226.00
P/S ratio (TTM) P/S ratio 227.00
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -87.40%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-11.85m
Free Cash Flow (TTM) Free Cash Flow $-8.61m
Cash position $150.00k
EPS (TTM) EPS $-12.21
Short interest 4.85%
Show more

Is Sonnet BioTherapeutics Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

Buy
100%

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.02 0.02
87% 87%
100%
- Direct Costs 0.08 0.08
0% 0%
400%
-0.06 -0.06
186% 186%
-300%
- Selling and Administrative Expenses 6.05 6.05
14% 14%
30,250%
- Research and Development Expense 5.65 5.65
51% 51%
28,250%
-12 -12
36% 36%
-58,850%
- Depreciation and Amortization 0.08 0.08
0% 0%
400%
EBIT (Operating Income) EBIT -12 -12
36% 36%
-59,248%
Net Profit -7.44 -7.44
60% 60%
-37,200%

In millions USD.

Don't miss a Thing! We will send you all news about Sonnet BioTherapeutics Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
6 days ago
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company's website .
Neutral
GlobeNewsWire
12 days ago
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
Neutral
GlobeNewsWire
19 days ago
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equiv...
More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office United States
CEO Pankaj Mohan
Employees 13
Founded 2011
Website www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today